JP2018502828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502828A5 JP2018502828A5 JP2017527368A JP2017527368A JP2018502828A5 JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5 JP 2017527368 A JP2017527368 A JP 2017527368A JP 2017527368 A JP2017527368 A JP 2017527368A JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- neoepitope
- present
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 87
- 206010028980 Neoplasm Diseases 0.000 claims description 63
- 201000011510 cancer Diseases 0.000 claims description 48
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims description 24
- 230000035772 mutation Effects 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 102100038078 CD276 antigen Human genes 0.000 claims description 8
- 101710185679 CD276 antigen Proteins 0.000 claims description 8
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 8
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 208000000649 small cell carcinoma Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 108091035707 Consensus sequence Proteins 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims description 4
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 4
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 102100028749 Neuritin Human genes 0.000 claims description 4
- 101710189685 Neuritin Proteins 0.000 claims description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000033616 DNA repair Effects 0.000 description 8
- 102000043129 MHC class I family Human genes 0.000 description 8
- 108091054437 MHC class I family Proteins 0.000 description 8
- 230000000869 mutational effect Effects 0.000 description 6
- 230000007704 transition Effects 0.000 description 5
- -1 DNA-PK Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 102100031441 Cell cycle checkpoint protein RAD17 Human genes 0.000 description 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 2
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 2
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101001130422 Homo sapiens Cell cycle checkpoint protein RAD17 Proteins 0.000 description 2
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 2
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 2
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 229910015837 MSH2 Inorganic materials 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000007482 whole exome sequencing Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129458A JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
| JP2024107117A JP2024125234A (ja) | 2014-11-21 | 2024-07-03 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083088P | 2014-11-21 | 2014-11-21 | |
| US62/083,088 | 2014-11-21 | ||
| US201562132381P | 2015-03-12 | 2015-03-12 | |
| US62/132,381 | 2015-03-12 | ||
| PCT/US2015/062208 WO2016081947A2 (en) | 2014-11-21 | 2015-11-23 | Determinants of cancer response to immunotherapy by pd-1 blockade |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135853A Division JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Ｐｄ−１遮断による免疫療法の癌奏効の決定因子 |
| JP2022129458A Division JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018502828A JP2018502828A (ja) | 2018-02-01 |
| JP2018502828A5 true JP2018502828A5 (enExample) | 2019-01-10 |
| JPWO2016081947A5 JPWO2016081947A5 (enExample) | 2022-09-01 |
| JP7173733B2 JP7173733B2 (ja) | 2022-11-16 |
Family
ID=56014697
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527368A Active JP7173733B2 (ja) | 2014-11-21 | 2015-11-23 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
| JP2020135853A Withdrawn JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Ｐｄ−１遮断による免疫療法の癌奏効の決定因子 |
| JP2022129458A Active JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
| JP2024107117A Pending JP2024125234A (ja) | 2014-11-21 | 2024-07-03 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135853A Withdrawn JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Ｐｄ−１遮断による免疫療法の癌奏効の決定因子 |
| JP2022129458A Active JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
| JP2024107117A Pending JP2024125234A (ja) | 2014-11-21 | 2024-07-03 | Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180291074A1 (enExample) |
| EP (2) | EP3220950A4 (enExample) |
| JP (4) | JP7173733B2 (enExample) |
| CN (2) | CN107206064B (enExample) |
| AU (3) | AU2015349644B2 (enExample) |
| CA (1) | CA2968059A1 (enExample) |
| HK (1) | HK1244440A1 (enExample) |
| MA (1) | MA40737A (enExample) |
| WO (1) | WO2016081947A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| US9765147B2 (en) | 2014-10-29 | 2017-09-19 | Five Prime Therapeutics, Inc. | Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| CA3008437A1 (en) | 2016-01-08 | 2017-07-13 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
| CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| JP2019509282A (ja) | 2016-02-29 | 2019-04-04 | ファウンデーション・メディシン・インコーポレイテッド | 癌の治療方法 |
| EP3804620B1 (en) * | 2016-03-01 | 2022-02-16 | North Carolina State University | Enhanced cancer immunotherapy by microneedle patch-assisted delivery |
| BR112018016920A2 (pt) * | 2016-03-02 | 2019-01-02 | Toray Industries, Inc. | indutor da imunidade, célula apresentadora de antígeno isolada, célula t isolada, polipeptídeo, agente para tratar ou prevenir o câncer e método de tratamento ou prevenção do câncer |
| MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
| WO2018003995A1 (ja) * | 2016-07-01 | 2018-01-04 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
| US11875877B2 (en) | 2016-08-25 | 2024-01-16 | Nantomics, Llc | Immunotherapy markers and uses therefor |
| CA3038712A1 (en) * | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2018067937A1 (en) | 2016-10-07 | 2018-04-12 | Omniseq, Inc. | Methods and systems for determining personalized therapies |
| WO2018132753A1 (en) * | 2017-01-13 | 2018-07-19 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| US12331359B2 (en) | 2017-01-18 | 2025-06-17 | Michael Laessig | Neoantigens and uses thereof for treating cancer |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| WO2018145023A1 (en) * | 2017-02-06 | 2018-08-09 | Novartis Ag | Method of predicting response to immunotherapy |
| WO2018151601A1 (en) * | 2017-02-17 | 2018-08-23 | Stichting Vumc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
| SG11201908530QA (en) | 2017-03-20 | 2019-10-30 | Genocea Biosciences Inc | Treatment methods |
| KR20250036268A (ko) * | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| IL271888B2 (en) | 2017-07-21 | 2024-09-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
| EP3658914A1 (en) * | 2017-07-28 | 2020-06-03 | Bristol-Myers Squibb Company | Predictive peripheral blood biomarker for checkpoint inhibitors |
| MX2020002301A (es) * | 2017-09-13 | 2020-07-13 | Five Prime Therapeutics Inc | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. |
| US20200268831A1 (en) * | 2017-09-15 | 2020-08-27 | The Texas A&M University System | Methods for enhancing immunotherapy in the treatment of cancer |
| CN111432837A (zh) | 2017-09-25 | 2020-07-17 | 纪念斯隆凯特琳癌症中心 | 肿瘤突变负荷和检查点免疫疗法 |
| US20200362418A1 (en) * | 2017-10-02 | 2020-11-19 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| US11810672B2 (en) | 2017-10-12 | 2023-11-07 | Nantomics, Llc | Cancer score for assessment and response prediction from biological fluids |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| EP3704268B1 (en) | 2017-11-03 | 2025-01-22 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| WO2019095017A1 (en) * | 2017-11-17 | 2019-05-23 | Gmdx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| WO2019109086A1 (en) * | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| JP6975350B2 (ja) * | 2018-05-03 | 2021-12-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 腫瘍突然変異量の測定のための代理マーカーおよび方法 |
| WO2019211489A1 (en) * | 2018-05-04 | 2019-11-07 | Merck Patent Gmbh | COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER |
| CN120193081A (zh) | 2018-07-23 | 2025-06-24 | 夸登特健康公司 | 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统 |
| US20210292851A1 (en) | 2018-07-27 | 2021-09-23 | Roche Sequencing Solutions, Inc. | Method of monitoring effectiveness of immunotherapy of cancer patients |
| EP3845236A4 (en) * | 2018-08-29 | 2022-07-27 | Tokyo Metropolitan Institute of Medical Science | ANTI-TUMOR AGENT TARGETING AN HGF-REGULATED TYROSINE KINASE (HGS) SUBSTRATE |
| AU2019328344B2 (en) | 2018-08-31 | 2025-06-12 | Guardant Health, Inc. | Microsatellite instability detection in cell-free DNA |
| WO2020102674A1 (en) * | 2018-11-15 | 2020-05-22 | Personal Genome Diagnostics Inc. | Method of improving prediction of response for cancer patients treated with immunotherapy |
| WO2020121226A1 (en) * | 2018-12-12 | 2020-06-18 | Medimmune, Llc | Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer |
| EP3982954A4 (en) * | 2019-06-14 | 2024-01-03 | The Trustees of Columbia University in the City of New York | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA |
| WO2021087381A1 (en) * | 2019-11-01 | 2021-05-06 | Memorial Sloan Kettering Cancer Center | Hla class i sequence divergence and cancer therapy |
| GB202003669D0 (en) * | 2020-03-13 | 2020-04-29 | Univ Oxford Innovation Ltd | Method for identifying neo-antigens |
| CN115885050A (zh) | 2020-04-28 | 2023-03-31 | 基因泰克公司 | 用于非小细胞肺癌免疫疗法的方法和组合物 |
| EP4158070A4 (en) * | 2020-06-01 | 2025-05-07 | GMDx Co Pty Ltd | METHODS FOR PREDICTING CANCER PROGRESSION |
| CN112309502B (zh) * | 2020-10-14 | 2024-09-20 | 深圳市新合生物医疗科技有限公司 | 一种计算肿瘤新抗原负荷的方法及系统 |
| WO2022099004A1 (en) * | 2020-11-06 | 2022-05-12 | The General Hospital Corporation | Methods for characterizing biological samples |
| WO2022235482A1 (en) * | 2021-05-03 | 2022-11-10 | Rutgers, The State University Of New Jersey | Immunotherapy for inflammatory bowel disease and/or cancer |
| CN113030475B (zh) * | 2021-05-25 | 2021-08-10 | 泛肽生物科技(浙江)有限公司 | 一种基于细胞线粒体质量评估的t细胞pd-1检测方法 |
| CN113355424B (zh) * | 2021-07-14 | 2022-03-25 | 江苏先声医学诊断有限公司 | Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| WO2024216165A1 (en) | 2023-04-12 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Computational methods for selecting personalized neoantigen vaccines |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033497A1 (en) | 2002-08-13 | 2004-02-19 | Alarcon-Riquelme Marta E. | Polymorphisms of PD-1 |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| EP2499486A4 (en) * | 2009-11-13 | 2013-11-27 | Infinity Pharmaceuticals Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| KR101958753B1 (ko) * | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| KR102315754B1 (ko) * | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| US20130225433A1 (en) * | 2012-02-29 | 2013-08-29 | The Regents Of The Universitys Of Michagan | Prostate cancer markers and uses thereof |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| AU2013323368B2 (en) * | 2012-09-28 | 2019-03-21 | The University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
| KR20160102314A (ko) * | 2014-01-02 | 2016-08-29 | 메모리얼 슬로안-케터링 캔서 센터 | 면역 치료요법에 대한 암 반응의 결정인자 |
| CA2966660A1 (en) * | 2014-11-13 | 2016-05-19 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| CN111432837A (zh) * | 2017-09-25 | 2020-07-17 | 纪念斯隆凯特琳癌症中心 | 肿瘤突变负荷和检查点免疫疗法 |
-
2015
- 2015-11-22 MA MA040737A patent/MA40737A/fr unknown
- 2015-11-23 EP EP15861224.2A patent/EP3220950A4/en not_active Ceased
- 2015-11-23 HK HK18103939.8A patent/HK1244440A1/zh unknown
- 2015-11-23 WO PCT/US2015/062208 patent/WO2016081947A2/en not_active Ceased
- 2015-11-23 CN CN201580073049.2A patent/CN107206064B/zh active Active
- 2015-11-23 CN CN202210026426.9A patent/CN114672559A/zh active Pending
- 2015-11-23 CA CA2968059A patent/CA2968059A1/en active Pending
- 2015-11-23 EP EP24157218.9A patent/EP4393546A3/en active Pending
- 2015-11-23 AU AU2015349644A patent/AU2015349644B2/en active Active
- 2015-11-23 JP JP2017527368A patent/JP7173733B2/ja active Active
- 2015-11-23 US US15/528,385 patent/US20180291074A1/en not_active Abandoned
-
2019
- 2019-02-22 US US16/283,555 patent/US10993998B2/en active Active
-
2020
- 2020-08-11 JP JP2020135853A patent/JP2020196732A/ja not_active Withdrawn
-
2021
- 2021-03-15 US US17/202,173 patent/US12485162B2/en active Active
- 2021-08-09 AU AU2021215099A patent/AU2021215099A1/en not_active Abandoned
-
2022
- 2022-08-16 JP JP2022129458A patent/JP7550193B2/ja active Active
-
2024
- 2024-07-03 JP JP2024107117A patent/JP2024125234A/ja active Pending
- 2024-12-12 AU AU2024278364A patent/AU2024278364A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502828A5 (enExample) | ||
| WO2016081947A4 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| Foy et al. | Non-viral precision T cell receptor replacement for personalized cell therapy | |
| Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
| Klebanoff et al. | T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome | |
| JP2017504324A5 (enExample) | ||
| JP7611836B2 (ja) | 抗原特異的ｔ細胞の同定のための組成物と方法 | |
| Chen et al. | Elements of cancer immunity and the cancer–immune set point | |
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| JP7328211B2 (ja) | Ｔｃｒ及びペプチド | |
| US20240269179A1 (en) | Neoantigens as targets for immunotherapy | |
| AU2016339022B2 (en) | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor | |
| CN119864090A (zh) | 用于预测hla ii类特异性表位及表征cd4+t细胞的方法和系统 | |
| RU2016131207A (ru) | Детерминанты ответа раковой опухоли на иммунотерапию | |
| Williamson et al. | Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury | |
| JP2019524106A (ja) | 有効性が増強された治療法のための疾患特異的標的としてのネオエピトープの選択 | |
| Mangolini et al. | Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape | |
| CN116097096A (zh) | 多发性骨髓瘤中的免疫治疗靶点及其鉴定方法 | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| Ghorashian et al. | CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor | |
| JP2018536225A (ja) | ウイルスネオエピトープおよびその使用 | |
| Kuehm et al. | Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity | |
| Wu et al. | RNA polymerase II pausing factor NELF in CD8+ T cells promotes antitumor immunity | |
| Blunt et al. | KIR2DS2 expression identifies NK cells with enhanced anticancer activity | |
| Xu et al. | Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade |